These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

976 related articles for article (PubMed ID: 33550043)

  • 41. Safety profile of COVID-19 drugs in a real clinical setting.
    Chiu MN; Bhardwaj M; Sah SP
    Eur J Clin Pharmacol; 2022 May; 78(5):733-753. PubMed ID: 35088108
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Potential Repurposed Therapeutics and New Vaccines against COVID-19 and Their Clinical Status.
    Banday AH; Shameem SA; Ajaz SJ
    SLAS Discov; 2020 Dec; 25(10):1097-1107. PubMed ID: 32692266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stopping pandemics before they start: Lessons learned from SARS-CoV-2.
    Edwards AM; Baric RS; Saphire EO; Ulmer JB
    Science; 2022 Mar; 375(6585):1133-1139. PubMed ID: 35271333
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug repurposing approach to fight COVID-19.
    Singh TU; Parida S; Lingaraju MC; Kesavan M; Kumar D; Singh RK
    Pharmacol Rep; 2020 Dec; 72(6):1479-1508. PubMed ID: 32889701
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Remdesivir against COVID-19 and Other Viral Diseases.
    Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An in vitro study of dual drug combinations of anti-viral agents, antibiotics, and/or hydroxychloroquine against the SARS-CoV-2 virus isolated from hospitalized patients in Surabaya, Indonesia.
    Purwati ; Miatmoko A; Nasronudin ; Hendrianto E; Karsari D; Dinaryanti A; Ertanti N; Ihsan IS; Purnama DS; Asmarawati TP; Marfiani E; Yulistiani ; Rosyid AN; Wulaningrum PA; Setiawan HW; Siswanto I; Tri Puspaningsih NN
    PLoS One; 2021; 16(6):e0252302. PubMed ID: 34143818
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.
    Won JH; Lee H
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33371468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. COVID-19: Discovery, diagnostics and drug development.
    Asselah T; Durantel D; Pasmant E; Lau G; Schinazi RF
    J Hepatol; 2021 Jan; 74(1):168-184. PubMed ID: 33038433
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential approaches to combat COVID-19: a mini-review.
    Sarwar Z; Ahmad T; Kakar S
    Mol Biol Rep; 2020 Dec; 47(12):9939-9949. PubMed ID: 33185828
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A Comprehensive Update of Anti-COVID-19 Activity of Heterocyclic Compounds.
    Nazir MS; Ahmad M; Aslam S; Rafiq A; Al-Hussain SA; Zaki MEA
    Drug Des Devel Ther; 2024; 18():1547-1571. PubMed ID: 38737333
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The FDA-Approved Drug Cobicistat Synergizes with Remdesivir To Inhibit SARS-CoV-2 Replication
    Shytaj IL; Fares M; Gallucci L; Lucic B; Tolba MM; Zimmermann L; Adler JM; Xing N; Bushe J; Gruber AD; Ambiel I; Taha Ayoub A; Cortese M; Neufeldt CJ; Stolp B; Sobhy MH; Fathy M; Zhao M; Laketa V; Diaz RS; Sutton RE; Chlanda P; Boulant S; Bartenschlager R; Stanifer ML; Fackler OT; Trimpert J; Savarino A; Lusic M
    mBio; 2022 Apr; 13(2):e0370521. PubMed ID: 35229634
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Broad-spectrum prodrugs with anti-SARS-CoV-2 activities: Strategies, benefits, and challenges.
    Wang Z; Yang L
    J Med Virol; 2022 Apr; 94(4):1373-1390. PubMed ID: 34897729
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Drug Discovery Strategies for SARS-CoV-2.
    Shyr ZA; Gorshkov K; Chen CZ; Zheng W
    J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Old and re-purposed drugs for the treatment of COVID-19.
    Jean SS; Hsueh PR
    Expert Rev Anti Infect Ther; 2020 Sep; 18(9):843-847. PubMed ID: 32419524
    [No Abstract]   [Full Text] [Related]  

  • 55. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
    Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
    Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effective Treatment of COVID-19 Infection with Repurposed Drugs: Case Reports.
    Enyeji AM; Arora A; Mangat HS
    Viral Immunol; 2024 Aug; 37(6):298-307. PubMed ID: 39096169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. COVID-19 Infection: Targeting Possibilities for Treatment.
    Haider T; Gour V; Pandey V; Kanwar IL; Tiwari R; Vishwakarma M; Bakshi AK; Sarkar A; Yadav R; Soni S; Soni V
    Crit Rev Ther Drug Carrier Syst; 2021; 38(3):75-115. PubMed ID: 34348019
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Narrative Overview of Coronavirus Infection: Clinical Signs and Symptoms, Viral Entry and Replication, Treatment Modalities, and Management.
    Chavda V; Yadav D; Parmar H; Brahmbhatt R; Patel B; Madhwani K; Jain M; Song M; Patel S
    Curr Top Med Chem; 2024; 24(21):1883-1916. PubMed ID: 38859776
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment.
    Sahin G; Akbal-Dagistan O; Culha M; Erturk A; Basarir NS; Sancar S; Yildiz-Pekoz A
    J Pharm Sci; 2022 Oct; 111(10):2652-2661. PubMed ID: 35691607
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical Trials of Repurposed Antivirals for SARS-CoV-2.
    Martinez MA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32631826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.